$72.80
Value $11.4B
TECH and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$72.80
Value $11.4B
$407.46
Value $370B
Bio-Techne (TECH) has a market value of $11.4B and UnitedHealth (UNH) $370B. Over the last year, with dividends, TECH moved +19.4% and UNH +23.4%. The P/E is 66.5 for TECH and 23.3 for UNH. Dividend yield: TECH 0.44%, UNH 2.22%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TECH$11.4B
UNH$370B
UNH is 32 times TECH
Revenue, 12 months
TECH$1.2B
UNH$450B
UNH is 366 times TECH
Net income, 12 months
TECH$172M
UNH$15.9B
UNH is 92 times TECH
Operating margin
TECH19.6%
UNH5.3%
14.3 points apart
ROIC
TECH7.7%
UNH11.3%
3.6 points apart
P/E
TECH66.5
UNH23.3
TECH is 2.9 times UNH
Dividend yield
TECH0.4%
UNH2.2%
1.8 points apart
5-year return
TECH-40.9%
UNH-2.8%
38.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TECH-40.9%
UNH-2.8%
| Period | TECHWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +19.4%Price +18.6% | +23.4%Price +20.2% |
| 3 years since November 13, 2023 | +29.5%+9.0% a yearPrice +27.5% | -20.0%-7.2% a yearPrice -24.9% |
| 5 years since November 12, 2021 | -40.9%-10.0% a yearPrice -42.3% | -2.8%-0.6% a yearPrice -11.2% |
| 10 years since November 16, 2016 | +193.3%+11.4% a yearPrice +177.1% | +217.6%+12.2% a yearPrice +169.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TECHBio-TechneUNHUnitedHealth
| Price | $72.80 | $407.46 |
|---|---|---|
| Market value | $11.4B | $370B |
| Enterprise value (EV) | $11.5B | $416B |
| P/E | 66.5 | 23.3 |
| P/E, 5-year median | 56.6 | 25.0 |
| P/B | 5.3 | 3.6 |
| EV/EBIT | 47.7 | 17.4 |
| Free cash flow yield | 2.7% | 6.2% |
| Revenue, 12 months | $1.2B | $450B |
|---|---|---|
| Net income, 12 months | $172M | $15.9B |
| Free cash flow, 12 months | $308M | $22.8B |
| Earnings per share, 12 months | $1.09 | $17.52 |
| Revenue growth, year on year | -0.4% | 11.8% |
| Revenue growth a year, past | +5.5%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | +5.9%over 5 years | -3.8%over 5 years |
| Gross margin | 65.8% | 88.3% |
|---|---|---|
| Operating margin | 19.6% | 5.3% |
| Net margin | 14.0% | 3.5% |
| ROIC | 7.7% | 11.3% |
| ROE | 8.3% | 15.5% |
| Cash | $350M | $28.5B |
|---|---|---|
| Total debt | $486M | $74.3B |
| Net debt / EBITDA | 0.2 | 1.6 |
| Interest cover | 27.2× | 6.2× |
| Dividend yield | 0.4% | 2.2% |
|---|---|---|
| Dividend per share, 12 months | $0.32 | $9.06 |
| Dividend growth a year, past | +0.0%over 5 years | +12.6%over 5 years |
| Buyback yield | 0.4% | 1.5% |
| Shareholder yield | 0.8% | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($370B) is about 32.3 times Bio-Techne ($11.4B), at today's prices.
Since November 16, 2016, TECH's price moved +177.1% and UNH's +169.0%. With dividends: TECH +193.3% (+11.4% a year), UNH +217.6% (+12.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.44% for Bio-Techne and 2.22% for UnitedHealth. Over the last twelve months they paid $0.32 and $9.06 per share.
At today's price, the P/E is 66.5 for TECH and 23.3 for UNH. The median of the last five years was 56.6 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 14.0% for Bio-Techne and 3.5% for UnitedHealth, and the operating margin 19.6% and 5.3%. Revenue was $1.2B and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.